Skip to content

Oxygen for Intrauterine Resuscitation of Category II Fetal Heart Tracings

Oxygen for Category II Intrauterine Fetal Resuscitation: A Randomized, Noninferiority Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02741284
Acronym
O2C2
Enrollment
114
Registered
2016-04-18
Start date
2016-06-30
Completion date
2020-12-31
Last updated
2021-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Electronic Fetal Monitoring, Fetal Hypoxia, Fetal-Placental Circulation

Brief summary

Maternal oxygen administration for concerning fetal heart rate tracing (FHT) patterns is common practice on Labor and Delivery units in the United States. Despite the broad use of oxygen, it is unclear if this practice is beneficial for the fetus. The purpose of this study is to compare oxygen to room air in patients with Category II fetal heart tracings with regard to neonatal acid-base status, subsequent tracings, and production of reactive oxygen species

Detailed description

Maternal oxygen administration for concerning fetal heart rate tracing (FHT) patterns is common practice on Labor and Delivery units in the United States. Despite the broad use of oxygen, it is unclear if this practice is beneficial for the fetus. Category II FHT, as defined by the National Institute of Child Health and Human Development (NICHD) (Robinson), is a broad class of FHT patterns that may suggest cord compression and/or placental insufficiency for which oxygen is most commonly administered. Although some animal and human studies (Khazin, Althabe) have demonstrated that maternal hyperoxygenation can alleviate such fetal heart rate decelerations, this purported benefit has not been shown to translate into improved fetal outcomes, particularly in relation to acid-base status. In fact, some studies suggest harm with oxygen use due to lower umbilical artery pH and increased delivery room resuscitation (Nesterenko, Thorp) or increased free radical activity (Khaw). Given the indeterminate evidence for this ubiquitously employed resuscitation technique, there is an urgent need to further study the utility of maternal oxygen administration in labor for fetal benefit. We propose a randomized controlled non-inferiority trial comparing oxygen to room air in patients with Category II FHT. Our central hypothesis is that room air alone is not inferior to oxygen administration with regard to neonatal acid-base status and FHT and may in fact, be a safer option for resuscitation due to less production of reactive oxygen species. Primary Aim: Determine the effect of maternal oxygen administration for Category II FHT on arterial umbilical cord lactate. Hypothesis: Room air, as a substitute for oxygen supplementation, is no different than oxygen in altering the acid-base status of the neonate as reflected in umbilical arterial (UA) lactate. Fetal hypo-oxygenation, as reflected by decelerations in the FHT, results in metabolic acidosis due to a shift from aerobic to anaerobic metabolism in which lactate and hydrogen ion production significantly increase causing a decrease in pH (Tuuli). Elevated umbilical cord lactate has been shown to be a surrogate for fetal metabolic acidosis and resultant neonatal morbidity (Tuuli, Westgren). The theorized benefit of maternal oxygen administration is increased oxygen delivery to the fetus resulting in reversal of anaerobic metabolism/ metabolic acidosis. This, however, has not been substantiated by evidence thus far. Women with persistent Category II FHT tracing will be randomly assigned to supplemental oxygen or room air. The primary outcome will be umbilical arterial lactate level, and secondary outcomes will be other umbilical cord gas parameters including UA pH, UV oxygen saturation, and UA base deficit. Secondary Aim #1: Characterize the effect of oxygen administration on fetal heart tracing patterns Hypothesis: Oxygen administration will be associated with a rate of persistent Category II FHT that is not different from those exposed to room air. Oxygen is typically administered as a response to FHT interpretation. Evidence thus far shows that Category II FHT are associated with a wide spectrum of neonatal outcomes and therefore do not uniformly reflect fetal acid-base status (Cahill, Frey). Hence, evaluating the effect of oxygen on subsequent FHT categorization is pivotal to labor management. The outcome that will be investigated is rate of persistent Category II FHT after intervention. Secondary Aim #2: Evaluate the safety of oxygen administration by measuring reactive oxygen species (ROS) in maternal and neonatal blood. Hypothesis: Oxygen administration will be associated with increased oxidative stress in maternal and neonatal cord blood as represented by malondialdehyde (MDA). Over-oxygenation can result in free radical or ROS formation that have detrimental downstream effects. The presence of reactive oxygen species results in degradation of lipids in the cell membrane and resultant formation of malondialdehyde (MDA) (Dalle-Donne), which has been studied as a surrogate for oxidative stress (Ilhan, Pryor, Suhail, Lorente). This study will be a prospective, randomized non inferiority trial to be conducted a single center. This study will include term, singleton patients admitted to Labor& Delivery for spontaneous labor or labor induction. Multiples, significant fetal anomalies, Category III FHT, umbilical artery doppler abnormalities and preterm pregnancies will be excluded. Additionally, women will be excluded if oxygen is required for maternal indications such as hypooxygenation or cardiopulmonary disease. Our primary objective will be umbilical cord lactate. Secondary objectives include additional cord gas parameters including umbilical artery pH, umbilical artery base deficit, and umbilical vein oxygen saturation; FHT categorization and deceleration patterns; maternal and umbilical cord blood measurement of malondialdehyde. Women will be consented at time of admission for labor and randomized when at least 6cm dilated with Category II FHT necessitating provider intervention.

Interventions

DRUG10L Oxygen by nonrebreather mask

Sponsors

Washington University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Term, singleton patients admitted to Labor& Delivery for spontaneous labor or labor induction

Exclusion criteria

* Multiple pregnancy * Significant fetal anomalies * Category III FHT * Umbilical artery doppler abnormalities * Maternal hypooxygenation or need for oxygen

Design outcomes

Primary

MeasureTime frameDescription
Mean Umbilical Artery Lactate at DeliveryAt deliveryDetermined by umbilical artery cord gas collected at time of delivery and only in patients with paired (umbilical artery and umbilical vein) cord gases.

Secondary

MeasureTime frameDescription
Umbilical Artery pHAt time of deliveryDetermined by umbilical artery cord gas collected at time of delivery and only in patients with paired (umbilical artery and umbilical vein) cord gases.
Mode of DeliveryAt deliveryDelivery via Cesarean section, operative vaginal delivery (forceps or vacuum), or spontaneous vaginal delivery
Umbilical Artery pO2Time of deliveryPartial pressure of oxygen as collected on cord gases at time of delivery
Umbilical Artery Base DeficitAt time of deliveryAs determined by cord gas collection at time of delivery
Umbilical Artery pCO2At time of deliveryPartial pressure of carbon dioxide as collected on cord gases at time of delivery

Other

MeasureTime frameDescription
Number of Patients With Resolved Recurrent Decelerations60 minutes after randomizationNumber of patients with resolution of recurrent variable or recurrent late decelerations within 60 minutes of randomization

Countries

United States

Participant flow

Participants by arm

ArmCount
Room Air
Room air, no mask
51
Oxygen
10L oxygen by nonrebreather mask
48
Total99

Baseline characteristics

CharacteristicRoom AirOxygenTotal
Age, Continuous27.8 years
STANDARD_DEVIATION 5.3
27.3 years
STANDARD_DEVIATION 6.3
27.5 years
STANDARD_DEVIATION 5.8
Alcohol2 Participants0 Participants2 Participants
Body mass index27.7 kg/m2
STANDARD_DEVIATION 7.3
26.9 kg/m2
STANDARD_DEVIATION 6.5
27.3 kg/m2
STANDARD_DEVIATION 6.9
Chorioamnionitis0 Participants0 Participants0 Participants
Chronic hypertension6 Participants3 Participants9 Participants
Epidural50 Participants44 Participants94 Participants
Gestational age at delivery39.1 weeks
STANDARD_DEVIATION 1.1
39.2 weeks
STANDARD_DEVIATION 1.1
39.1 weeks
STANDARD_DEVIATION 1.1
Hematocrit on admission32.5 Percentage of red blood cells
STANDARD_DEVIATION 3.2
32.8 Percentage of red blood cells
STANDARD_DEVIATION 3.5
32.6 Percentage of red blood cells
STANDARD_DEVIATION 3.3
Illicit drug use8 Participants12 Participants20 Participants
Induction of labor36 Participants34 Participants70 Participants
Nulliparity6 Participants5 Participants11 Participants
Oxytocin45 Participants43 Participants88 Participants
Preeclampsia3 Participants0 Participants3 Participants
Pregestational diabetes0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants3 Participants3 Participants
Race (NIH/OMB)
Black or African American
40 Participants36 Participants76 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants1 Participants2 Participants
Race (NIH/OMB)
White
10 Participants8 Participants18 Participants
Sex: Female, Male
Female
51 Participants48 Participants99 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants
Tobacco use8 Participants6 Participants14 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 570 / 57
other
Total, other adverse events
0 / 570 / 57
serious
Total, serious adverse events
0 / 570 / 57

Outcome results

Primary

Mean Umbilical Artery Lactate at Delivery

Determined by umbilical artery cord gas collected at time of delivery and only in patients with paired (umbilical artery and umbilical vein) cord gases.

Time frame: At delivery

ArmMeasureValue (MEAN)
Room AirMean Umbilical Artery Lactate at Delivery3.5 mmol/L
OxygenMean Umbilical Artery Lactate at Delivery3.4 mmol/L
p-value: 0.6995% CI: [-0.5, 0.7]Wilcoxon (Mann-Whitney)
Secondary

Mode of Delivery

Delivery via Cesarean section, operative vaginal delivery (forceps or vacuum), or spontaneous vaginal delivery

Time frame: At delivery

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Room AirMode of DeliveryCesarean delivery2 Participants
Room AirMode of DeliveryCesarean delivery for non reassuring fetal status0 Participants
Room AirMode of DeliveryOperative vaginal delivery6 Participants
Room AirMode of DeliverySpontaenous vaginal delivery43 Participants
OxygenMode of DeliverySpontaenous vaginal delivery41 Participants
OxygenMode of DeliveryCesarean delivery6 Participants
OxygenMode of DeliveryOperative vaginal delivery1 Participants
OxygenMode of DeliveryCesarean delivery for non reassuring fetal status2 Participants
Comparison: Cesarean deliveryp-value: <0.0595% CI: [0.07, 1.48]Chi-squared
Comparison: Cesarean delivery for non reassuring fetal statusp-value: <0.0595% CI: [0, 0]Chi-squared
Comparison: Operative vaginal deliveryp-value: <0.0595% CI: [0.71, 45.2]Chi-squared
Secondary

Umbilical Artery Base Deficit

As determined by cord gas collection at time of delivery

Time frame: At time of delivery

ArmMeasureValue (MEAN)
Room AirUmbilical Artery Base Deficit-3.6 meq/L
OxygenUmbilical Artery Base Deficit-3.6 meq/L
p-value: 0.9995% CI: [-1, 1]t-test, 2 sided
Secondary

Umbilical Artery pCO2

Partial pressure of carbon dioxide as collected on cord gases at time of delivery

Time frame: At time of delivery

ArmMeasureValue (MEAN)
Room AirUmbilical Artery pCO255.9 mmHg
OxygenUmbilical Artery pCO257.4 mmHg
p-value: 0.4495% CI: [-5.4, 2.4]t-test, 2 sided
Secondary

Umbilical Artery pH

Determined by umbilical artery cord gas collected at time of delivery and only in patients with paired (umbilical artery and umbilical vein) cord gases.

Time frame: At time of delivery

ArmMeasureValue (MEAN)
Room AirUmbilical Artery pH7.26 pH units
OxygenUmbilical Artery pH7.25 pH units
Comparison: pHp-value: <0.0595% CI: [-0.01, 0.03]t-test, 2 sided
Secondary

Umbilical Artery pO2

Partial pressure of oxygen as collected on cord gases at time of delivery

Time frame: Time of delivery

ArmMeasureValue (MEAN)
Room AirUmbilical Artery pO219.7 mm Hg
OxygenUmbilical Artery pO224.4 mm Hg
p-value: 0.0695% CI: [-9.6, 0.1]t-test, 2 sided
Other Pre-specified

Number of Patients With Resolved Recurrent Decelerations

Number of patients with resolution of recurrent variable or recurrent late decelerations within 60 minutes of randomization

Time frame: 60 minutes after randomization

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Room AirNumber of Patients With Resolved Recurrent Decelerations49 Participants
OxygenNumber of Patients With Resolved Recurrent Decelerations43 Participants

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026